Axitinib

Product Details:

Axitinib (brand name Inlyta) is an oral prescription medication primarily used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs). 

How It Works

Axitinib is a highly selective, second-generation TKI that works by blocking specific abnormal proteins, namely vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. These receptors play a key role in the formation of new blood vessels that tumors need to grow and spread (a process called angiogenesis). By inhibiting these receptors, axitinib helps to slow or stop the growth and spread of cancer cells. 

Indications and Usage

Axitinib is approved for use in adults with advanced RCC in a few specific scenarios: 

As a first-line treatment: In combination with the immunotherapy drugs avelumab (Bavencio) or pembrolizumab (Keytruda).